Open-House-Biologika-Rabattverträge 2026-10 - Infliximab (Darreichungsform zur subkutanen Injektion)

Summary

The tender concerns rebate agreements for infliximab (dosage form for subcutaneous injection). It is an open-house procedure in which all suitable pharmaceutical companies may join on the same terms. The bidder must be a pharmaceutical company authorised to market the relevant medicine and must take into account the exclusion grounds, suitability requirements, contract performance conditions and the electronic process. The contract term is up to 24 months from 01/06/2026 and ends no later than 31/05/2028.